Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry
Copyright© 2020 Ferrata Storti Foundation..
Iron overload due to red blood cell (RBC) transfusions is associated with morbidity and mortality in lower-risk myelodysplastic syndrome (MDS) patients. Many studies have suggested improved survival after iron chelation therapy (ICT), but valid data are limited. The aim of this study was to assess the effect of ICT on overall survival and hematologic improvement in lower-risk MDS patients in the European MDS registry. We compared chelated patients with a contemporary, non-chelated control group within the European MDS registry, that met the eligibility criteria for starting iron chelation. A Cox proportional hazards model was used to assess overall survival (OS), treating receipt of chelation as a time-varying variable. Additionally, chelated and non-chelated patients were compared using a propensity-score matched model. Of 2,200 patients, 224 received iron chelation. The hazard ratio and 95% confidence interval for OS for chelated patients, adjusted for age, sex, comorbidity, performance status, cumulative RBC transfusions, Revised-International Prognostic Scoring System (IPSS-R), and presence of ringed sideroblasts was 0.50 (0.34-0.74). The propensity-score analysis, matched for age, sex, country, RBC transfusion intensity, ferritin level, comorbidity, performance status, and IPSS-R, and, in addition, corrected for cumulative RBC transfusions and presence of ringed sideroblasts, demonstrated a significantly improved OS for chelated patients with a hazard ratio of 0.42 (0.27-0.63) compared to non-chelated patients. Up to 39% of chelated patients reached an erythroid response. In conclusion, our results suggest that iron chelation may improve OS and hematopoiesis in transfused lower-risk MDS patients. This trial was registered at clinicaltrials.gov identifier: 00600860.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:105 |
|---|---|
| Enthalten in: |
Haematologica - 105(2020), 3 vom: 04. März, Seite 640-651 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
E1UOL152H7 |
|---|
| Anmerkungen: |
Date Completed 27.04.2021 Date Revised 27.04.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3324/haematol.2018.212332 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM298916673 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM298916673 | ||
| 003 | DE-627 | ||
| 005 | 20231225095216.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3324/haematol.2018.212332 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0996.xml |
| 035 | |a (DE-627)NLM298916673 | ||
| 035 | |a (NLM)31278207 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hoeks, Marlijn |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.04.2021 | ||
| 500 | |a Date Revised 27.04.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© 2020 Ferrata Storti Foundation. | ||
| 520 | |a Iron overload due to red blood cell (RBC) transfusions is associated with morbidity and mortality in lower-risk myelodysplastic syndrome (MDS) patients. Many studies have suggested improved survival after iron chelation therapy (ICT), but valid data are limited. The aim of this study was to assess the effect of ICT on overall survival and hematologic improvement in lower-risk MDS patients in the European MDS registry. We compared chelated patients with a contemporary, non-chelated control group within the European MDS registry, that met the eligibility criteria for starting iron chelation. A Cox proportional hazards model was used to assess overall survival (OS), treating receipt of chelation as a time-varying variable. Additionally, chelated and non-chelated patients were compared using a propensity-score matched model. Of 2,200 patients, 224 received iron chelation. The hazard ratio and 95% confidence interval for OS for chelated patients, adjusted for age, sex, comorbidity, performance status, cumulative RBC transfusions, Revised-International Prognostic Scoring System (IPSS-R), and presence of ringed sideroblasts was 0.50 (0.34-0.74). The propensity-score analysis, matched for age, sex, country, RBC transfusion intensity, ferritin level, comorbidity, performance status, and IPSS-R, and, in addition, corrected for cumulative RBC transfusions and presence of ringed sideroblasts, demonstrated a significantly improved OS for chelated patients with a hazard ratio of 0.42 (0.27-0.63) compared to non-chelated patients. Up to 39% of chelated patients reached an erythroid response. In conclusion, our results suggest that iron chelation may improve OS and hematopoiesis in transfused lower-risk MDS patients. This trial was registered at clinicaltrials.gov identifier: 00600860 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Iron Chelating Agents |2 NLM | |
| 650 | 7 | |a Iron |2 NLM | |
| 650 | 7 | |a E1UOL152H7 |2 NLM | |
| 700 | 1 | |a Yu, Ge |e verfasserin |4 aut | |
| 700 | 1 | |a Langemeijer, Saskia |e verfasserin |4 aut | |
| 700 | 1 | |a Crouch, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a de Swart, Louise |e verfasserin |4 aut | |
| 700 | 1 | |a Fenaux, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Symeonidis, Argiris |e verfasserin |4 aut | |
| 700 | 1 | |a Čermák, Jaroslav |e verfasserin |4 aut | |
| 700 | 1 | |a Hellström-Lindberg, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Sanz, Guillermo |e verfasserin |4 aut | |
| 700 | 1 | |a Stauder, Reinhard |e verfasserin |4 aut | |
| 700 | 1 | |a Holm, Mette Skov |e verfasserin |4 aut | |
| 700 | 1 | |a Mittelman, Moshe |e verfasserin |4 aut | |
| 700 | 1 | |a Mądry, Krzysztof |e verfasserin |4 aut | |
| 700 | 1 | |a Malcovati, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Tatic, Aurelia |e verfasserin |4 aut | |
| 700 | 1 | |a Almeida, Antonio Medina |e verfasserin |4 aut | |
| 700 | 1 | |a Germing, Ulrich |e verfasserin |4 aut | |
| 700 | 1 | |a Savic, Aleksandar |e verfasserin |4 aut | |
| 700 | 1 | |a Šimec, Njetočka Gredelj |e verfasserin |4 aut | |
| 700 | 1 | |a Culligan, Dominic |e verfasserin |4 aut | |
| 700 | 1 | |a Itzykson, Raphael |e verfasserin |4 aut | |
| 700 | 1 | |a Guerci-Bresler, Agnes |e verfasserin |4 aut | |
| 700 | 1 | |a Slama, Borhane |e verfasserin |4 aut | |
| 700 | 1 | |a Droste, Jackie |e verfasserin |4 aut | |
| 700 | 1 | |a van Marrewijk, Corine |e verfasserin |4 aut | |
| 700 | 1 | |a van de Loosdrecht, Arjan |e verfasserin |4 aut | |
| 700 | 1 | |a Blijlevens, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a van Kraaij, Marian |e verfasserin |4 aut | |
| 700 | 1 | |a Bowen, David |e verfasserin |4 aut | |
| 700 | 1 | |a de Witte, Theo |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Alex |e verfasserin |4 aut | |
| 700 | 0 | |a EUMDS Registry Participants |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Haematologica |d 1947 |g 105(2020), 3 vom: 04. März, Seite 640-651 |w (DE-627)NLM000081892 |x 1592-8721 |7 nnns |
| 773 | 1 | 8 | |g volume:105 |g year:2020 |g number:3 |g day:04 |g month:03 |g pages:640-651 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3324/haematol.2018.212332 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 105 |j 2020 |e 3 |b 04 |c 03 |h 640-651 | ||